This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jul;12(7):613-4.

doi: 10.1016/S1470-2045(11)70146-2. Epub 2011 Jun 12.

Combination therapy in metastatic renal cell carcinoma

Daniel Y C Heng¹

Affiliations

PMID: 21664868
DOI: 10.1016/S1470-2045(11)70146-2

Comment

Combination therapy in metastatic renal cell carcinoma

Daniel Y C Heng. Lancet Oncol. 2011 Jul.

. 2011 Jul;12(7):613-4.

doi: 10.1016/S1470-2045(11)70146-2. Epub 2011 Jun 12.

Author

Daniel Y C Heng¹

Affiliation

¹ Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Canada. daniel.heng@albertahealthservices.ca

PMID: 21664868
DOI: 10.1016/S1470-2045(11)70146-2

No abstract available

PubMed Disclaimer

Comment on

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B. Négrier S, et al. Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12. Lancet Oncol. 2011. PMID: 21664867 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science